The prognostic risk model constructed in this study, based on the four genes MPP5, SNX7, LSM12, and GALNT3, demonstrated promising predictive performance for radiotherapy outcomes in cervical cancer patients, particularly in the medium- to long-term follow-up, with an AUC of 0.75 at 3 years. This evidence concerns the gene PALS1 and cervical carcinoma.